Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio
KRISTOFFER TRIPPLAAR/SIPA VIA AP
A monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to Dupixent.
¿Cómo sabemos que el cambio climático es real?
Hace 44 minutos
.png)
No hay comentarios:
Publicar un comentario